United States Localized Scleroderma Market 2026 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

Global Localized Scleroderma Market is growing at a CAGR of 5% during the forecast period 2024-2031.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/localized-scleroderma-market?sb

Key Development:

United States: Recent Industry Developments

✅ In March 2026, Pfizer initiated a clinical research collaboration with a U.S. dermatology research network to evaluate targeted immunotherapy approaches for localized scleroderma treatment. The study focuses on reducing skin fibrosis using precision biologic therapies. It supports the development of safer long-term treatment options for autoimmune skin disorders.

✅ In February 2026, the U.S. FDA granted orphan drug designation to an investigational therapy developed by a biotechnology company for the treatment of localized scleroderma. The therapy targets inflammatory pathways responsible for abnormal collagen production. The designation encourages faster development of treatments for rare autoimmune diseases.

✅ In January 2026, Bristol Myers Squibb announced investment in autoimmune disease research programs focusing on fibrosis-related conditions including localized scleroderma. The program supports development of next-generation immunomodulatory drugs. It strengthens the company's pipeline in dermatology and rare disease therapeutics.

✅ In December 2025, AbbVie launched an expanded clinical trial in the United States evaluating JAK inhibitor therapy for inflammatory skin disorders including localized scleroderma. The trial studies safety and long-term efficacy in patients with limited skin involvement. It aims to improve targeted treatment options for chronic autoimmune conditions.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=localized-scleroderma-market

Japan: Recent Industry Developments

✅ In March 2026, Chugai Pharmaceutical announced research expansion in autoimmune skin diseases including localized scleroderma using antibody-based therapies. The project focuses on controlling immune-mediated fibrosis and inflammation. It supports Japan's innovation in biologic treatments for rare dermatological disorders.

✅ In February 2026, Takeda Pharmaceutical invested in rare disease drug development programs targeting connective tissue disorders including localized scleroderma. The initiative includes collaboration with academic hospitals for clinical evaluation. It aims to accelerate development of precision therapies for autoimmune diseases.

✅ In January 2026, Astellas Pharma launched a research program on fibrosis-related skin diseases to develop targeted small-molecule therapies for localized scleroderma. The program focuses on regulating immune signaling pathways. It strengthens Japan's pipeline in dermatology and immunology treatments.

✅ In December 2025, Mitsubishi Tanabe Pharma announced collaboration with Japanese universities to study new treatment approaches for localized scleroderma using anti-fibrotic compounds. The research focuses on preventing excessive collagen formation in skin tissue. It supports advancement of innovative therapies for rare autoimmune skin disorders.

Key Players:

=> Connote Healthcare, GLASIER WELLNESS INC., Pfizer Inc., Anant Pharmaceuticals Pvt. Ltd., Lxir Medilabs, NIKSAN PHARMACEUTICAL, Teva Pharmaceuticals USA, Inc., A.S. Lifesciences, Biomedica Remedies and SAKHIYA PHARMA CHEM among others.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/localized-scleroderma-market?sb

Key Segments:

By Type

Circumscribed Morphea dominates with 45% share, driven by its higher prevalence compared to other forms and relatively mild symptoms that lead to frequent diagnosis and treatment. Linear Morphea accounts for 30%, supported by its occurrence in children and adolescents, often requiring long-term monitoring and therapy. Generalized Morphea holds 25%, fueled by the need for intensive treatment due to wider skin involvement and higher risk of complications.

By Treatment

Drug Treatment leads with 60% share, driven by the widespread use of corticosteroids, immunosuppressants, and anti-inflammatory medications to control disease progression and reduce skin inflammation. Therapy accounts for 40%, supported by the use of phototherapy, physical therapy, and other supportive treatments to improve skin flexibility and prevent disability.

By End-User

Hospitals dominate with 55% share, due to the availability of specialized dermatology care, diagnostic facilities, and advanced treatment options for moderate to severe morphea cases. Specialty Clinics account for 30%, supported by increasing visits to dermatology and rheumatology clinics for early diagnosis and ongoing management. Others hold 15%, including research institutes and outpatient care centers providing supportive therapy and follow-up care.

By Region

North America - 35% Share
North America leads with 35%, driven by strong healthcare infrastructure, high awareness of rare skin disorders, and availability of advanced treatment options in the U.S. and Canada.

Europe - 25% Share
Europe holds 25%, supported by well-established dermatology care systems and increasing research activities related to autoimmune skin diseases across Germany, the U.K., France, and Italy.

Asia Pacific - 25% Share
Asia Pacific accounts for 25%, fueled by improving healthcare access, growing patient population, and rising diagnosis rates in China, India, Japan, and South Korea.

Middle East & Africa - 8% Share
The Middle East & Africa represent 8%, driven by gradual improvements in healthcare services and increasing awareness of skin disease treatments.

South America - 7% Share
South America holds 7%, supported by expanding healthcare infrastructure and growing dermatology treatment demand in Brazil, Argentina, and Chile.

FAQ

Q: What is the growth rate of the Localized Scleroderma Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 5% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.